Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.
<h4>Background</h4>Aldose reductase inhibitors (ARIs) can block the metabolism of the polyol pathway, and have been used to slow or reverse the progression of diabetic cardiovascular autonomic neuropathy (DCAN). The purpose of this study was to review the effectiveness and safety of ARIs...
Main Authors: | Xin Hu, Shengbing Li, Gangyi Yang, Hua Liu, Guenther Boden, Ling Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24533052/pdf/?tool=EBI |
Similar Items
-
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
by: Sharma S, et al.
Published: (2008-01-01) -
Enzymatic Characterization of Aldose Reductase and Its Inhibitors
by: Zivkovic, DaVena
Published: (2016) -
Aldose Reductase Differential Inhibitors in Green Tea
by: Francesco Balestri, et al.
Published: (2020-07-01) -
Dietary aldose reductase inhibitors and prevention of diabetic complications
by: Ameena Anjum, et al.
Published: (2021-01-01) -
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
by: Sangeetha Iyer, et al.
Published: (2019-11-01)